Joseph Holmes

Molecular biologist at Sosei Heptares | PhD in protein biochemistry | interests in GPCRs and Barnsley FC | views and opinions are my own

[Joseph Holmes @JosephHSheff]

@sophbrad Thanks very much Sophie 🥳

[Joseph Holmes @JosephHSheff]

So something big happened this weekend. I guess she's stuck with me a little while longer

[Joseph Holmes @JosephHSheff]

@TLRailUK @thetrainline Hi AM, appreciate its not your fault but can I ask what the disruption is? Services were running as normal when tickets were purchased at ~15:00

[Joseph Holmes @JosephHSheff]

@TLRailUK @thetrainline update please, every train from London bridge area to biggleswade is cancelled until early hours of the morning. With work tomorrow how on earth am I meant to get home?

[Joseph Holmes @JosephHSheff]

@dave_thesmith Congratulations, David! As a former student of yours, I can say it's thoroughly deserved

[Joseph Holmes @JosephHSheff]

1-year got you date. Photos of then and now, what a pup

[Gareth Richards @G_O_Richards]

Check out our latest review, published today.

Targeting the adrenomedullin-2 receptor for the discovery and development of novel anti-cancer agents https://t.co/qsDLEJnD7Q

[Joseph Holmes @JosephHSheff]

Dougie enjoying the nice weather in Costa del Biggleswade

[Joseph Holmes @JosephHSheff]

@MegPoxon Congratulations Meg!

[Joseph Holmes @JosephHSheff]

Innocent or up to no good?

[Nxera Pharma @NxeraPharma]

Sosei Heptares announces antitrust clearance of license agreement with Neurocrine Biosciences, and confirms it will receive an upfront payment of US$100m in Q4 2021. View PR: https://t.co/wK6BdxR3se

[Gareth Richards @G_O_Richards]

Our latest paper is out now.

Accelerated development with increased bone mass and skeletal response to loading suggest receptor activity modifying protein-3 as a bone anabolic target. https://t.co/bRnv5Mzc3p

[Nxera Pharma @NxeraPharma]

Watch this video to further explore the research collaboration between Sosei Heptares and @UofGlasgow – use of structure-based approaches to design drug candidates targeting the M1 receptor to improve cognition in AD patients. Published in @cellcellpress https://t.co/uFz8o3zkLB

[Nxera Pharma @NxeraPharma]

We have entered into a strategic collaboration and licensing agreement to develop novel muscarinic receptor agonists with Neurocrine Biosciences intends to study in the treatment for #schizophrenia, dementia and other neuropsychiatric disorders. View PR:https://t.co/yaKB4gQojt

[Nxera Pharma @NxeraPharma]

For the past three years, we have been supporting @Music4mymind as part of an employee-led charity fundraising initiative, which was inspired by the desire to assist people living with #Dementia and their families. Try their newly built App here: https://t.co/DPXNLsxbQM

[Martin Lewis @MartinSLewis]

Oh my... word.

****1 month ago****
Energy price cap £1,138/yr
Cheapest fix £1,177/yr
(for someone with typical usage)

****Today****
Energy price cap £1,277/yr
Cheapest fix £1,700/yr

Astronomical. Shocking. DONT SWITCH right now.

[Joseph Holmes @JosephHSheff]

@G_O_Richards Wishing you a speedy recovery Gareth

[Joseph Holmes @JosephHSheff]

@G_O_Richards Many congrats kamilla!

[Joseph Holmes @JosephHSheff]

@MegPoxon Many congrats, meg, and good luck in the new job! Sure you'll absolutely smash it 🥳